<DOC>
	<DOCNO>NCT01849939</DOCNO>
	<brief_summary>Usually Chronic lymphocytic leukemia ( CLL ) disease elderly patient . However , diagnosis young patient become frequently poor prognosis . The identification new prognostic factor permit early determination high risk population provide therapeutic intensification . Allogeneic transplantation hematopoietic stem cell transplantation ( AHSCT ) allow long-term remission case complete definitive eradication disease . After chemotherapy antibody , Minimal Residual Disease ( MRD ) negativity associate well disease-free survival . MRD negativity occur patient appearance GVHD , stop immunosuppression donor lymphocyte injection ( DLI ) . The negativity MRD first year post-transplant correlate good progression-free survival overall survival ( Dreger 2010 , Farina 2009 , Caballero 2005 , Algrin , 2011 ) . So , MRD negativity may objective AHSCT . The aim prospective study evaluate standardize preemptive immunointervention post-allograft immunosuppressive therapy modulation DLI administration accord MRD level . The objective obtain MRD negativity 12 month AHSCT .</brief_summary>
	<brief_title>Eradication Residual Disease Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Patients receive AHSCT Fludarabine-Busulfan base conditioning : - Fludarabine : 30 mg/m2/day - Day-6 Day-2 - Busulfan IV : 3.2 mg/kg/day - Day-5 Day-4 - ATG ( Anti-thymocyte Globulin ) : 2.5 mg/kg/day Day-2 Day-1 Preemptive immunointervention post AHSCT consist reduce immunosuppressive treatment less associated DLI accord : - presence absence severe Graft versus host disease ( GVHD ) ( acute grade 2 / chronic ) - presence absence response criterion response IWCLL - Getting blood MRD negative ( &lt; -10 ^ -4 ) evaluate flow cytometry</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Patients CLL ( Matutes score 4 5 ) stag A , B , C evolution criterion accord IWCLL 2008 lymphocytic lymphoma severity criterion ( EBMT criterion ) indicate allograft ( deletion 17p ) require treatment Age : 1870 year At least one follow criterion poor prognosis ( EBMT recommendation Dreger 2007 ) 1 . No response relapse within 12 month treatment purine analogue ( include `` fludarabine refractory '' i.e patient response &lt; PR / relapse within 6 month least 2 course Fludurabine ) 2. relapse within 24 month combination therapy include purine analog autograft , indication new start treatment 3 . Mutation/deletion 17p13 ( p53 ) indication treatment Partial response ( PR ) complete response ( CR ) last treatment ( IWCLL 2008 ) Residual mass &lt; 5 cm ( clinical CT scan ) Identical intrafamilial donor HLA ( mismatch ) absence family donor , unrelated donor 10/10 HLA A , B , C , DR , DQ commit give DLI ( see consent form donor ) Sorror score comorbidity : â‰¤ 2 Written informed consent Member beneficiary social security system Richter Syndrome Usual contraindication realisation allogeneic transplantation include Uncontrolled bacterial , viral fungal infection Pregnancy lactate woman Cardiac contraindication : Cardiac ejection fraction &lt; 50 % Pulmonary contraindication : DLCO &lt; 50 % Renal contraindication : Creatininine clearance &lt; 30 ml / min Hepatic contraindication : AST / ALT / total bilirubine &gt; 2 N except Gilbert disease localisation specific LLC HIV positivity Cancer evolution de novo occur previous 5 year except basal cell cancer skin carcinoma situ cervix uterus Affection psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Allogeneic transplantation hematopoietic stem cell transplantation</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Donor Lymphocyte Injection</keyword>
	<keyword>Preemptive immunointervention</keyword>
</DOC>